These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 18519781

  • 1. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.
    Ychou M, Azria D, Menkarios C, Faurous P, Quenet F, Saint-Aubert B, Rouanet P, Pèlegrin M, Bascoul-Mollevi C, Guerreau D, Saccavini JC, Mach JP, Artus JC, Pèlegrin A.
    Clin Cancer Res; 2008 Jun 01; 14(11):3487-93. PubMed ID: 18519781
    [Abstract] [Full Text] [Related]

  • 2. Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer.
    Ychou M, Pelegrin A, Faurous P, Robert B, Saccavini JC, Guerreau D, Rossi JF, Fabbro M, Buchegger F, Mach JP, Artus JC.
    Int J Cancer; 1998 Feb 09; 75(4):615-9. PubMed ID: 9466665
    [Abstract] [Full Text] [Related]

  • 3. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G, Buchegger F, Waibel R, Kuenzi G, Offord RE, Schubiger PA, Gillet M, Delaloye AB.
    Cancer Biother Radiopharm; 2001 Oct 09; 16(5):371-9. PubMed ID: 11776754
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.
    Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, Ghadimi BM, Wegener WA, Kovacs J, Horak ID, Becker H, Goldenberg DM.
    J Clin Oncol; 2005 Sep 20; 23(27):6763-70. PubMed ID: 16170184
    [Abstract] [Full Text] [Related]

  • 5. Radioimmunotherapy of colorectal cancer liver metastases: combination with radiotherapy.
    Buchegger F, Roth A, Allal A, Dupertuis YM, Slosman DO, Delaloye AB, Mach JP.
    Ann N Y Acad Sci; 2000 Jun 20; 910():263-9; discussion 269-70. PubMed ID: 10911919
    [Abstract] [Full Text] [Related]

  • 6. Combined radioimmunotherapy and radiotherapy of liver metastases from colorectal cancer: a feasibility study.
    Buchegger F, Allal AS, Roth A, Papazyan JP, Dupertuis Y, Mirimanoff RO, Gillet M, Pelegrin A, Mach JP, Slosman DO.
    Anticancer Res; 2000 Jun 20; 20(3B):1889-96. PubMed ID: 10928122
    [Abstract] [Full Text] [Related]

  • 7. Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group.
    Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg DM.
    Ann Surg Oncol; 2007 Sep 20; 14(9):2577-90. PubMed ID: 17570017
    [Abstract] [Full Text] [Related]

  • 8. Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas.
    Sharkey RM, Goldenberg DM, Vagg R, Pawlyk D, Wong GY, Siegel JA, Murthy S, Levine GM, Izon D, Gascon P.
    Cancer; 1994 Feb 01; 73(3 Suppl):864-77. PubMed ID: 8306272
    [Abstract] [Full Text] [Related]

  • 9. Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study.
    Sahlmann CO, Homayounfar K, Niessner M, Dyczkowski J, Conradi LC, Braulke F, Meller B, Beißbarth T, Ghadimi BM, Meller J, Goldenberg DM, Liersch T.
    Cancer; 2017 Feb 15; 123(4):638-649. PubMed ID: 27763687
    [Abstract] [Full Text] [Related]

  • 10. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
    Casey JL, King DJ, Chaplin LC, Haines AM, Pedley RB, Mountain A, Yarranton GT, Begent RH.
    Br J Cancer; 1996 Nov 15; 74(9):1397-405. PubMed ID: 8912535
    [Abstract] [Full Text] [Related]

  • 11. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
    Kraeber-Bodéré F, Faivre-Chauvet A, Saï-Maurel C, Campion L, Fiche M, Gautherot E, Le Boterff J, Barbet J, Chatal JF, Thédrez P.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies.
    Lane DM, Eagle KF, Begent RH, Hope-Stone LD, Green AJ, Casey JL, Keep PA, Kelly AM, Ledermann JA, Glaser MG.
    Br J Cancer; 1994 Sep 15; 70(3):521-5. PubMed ID: 8080740
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
    Sato N, Saga T, Sakahara H, Yao Z, Nakamoto Y, Zhang M, Kuroki M, Matsuoka Y, Iida Y, Konishi J.
    J Nucl Med; 1999 Apr 15; 40(4):685-92. PubMed ID: 10210230
    [Abstract] [Full Text] [Related]

  • 16. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.
    Buchegger F, Pfister C, Fournier K, Prevel F, Schreyer M, Carrel S, Mach JP.
    J Clin Invest; 1989 May 15; 83(5):1449-56. PubMed ID: 2708519
    [Abstract] [Full Text] [Related]

  • 17. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
    Mittal BB, Zimmer MA, Sathiaseelan V, Benson AB, Mittal RR, Dutta S, Rosen ST, Spies SM, Mettler JM, Groch MW.
    Cancer; 1996 Nov 01; 78(9):1861-70. PubMed ID: 8909304
    [Abstract] [Full Text] [Related]

  • 18. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F, Faibre-Chauvet A, Saï-Maurel C, Gautherot E, Fiche M, Campion L, Le Boterff J, Barbet J, Chatal JF, Thédrez P.
    J Nucl Med; 1999 Jan 01; 40(1):198-204. PubMed ID: 9935077
    [Abstract] [Full Text] [Related]

  • 19. Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients.
    Murray JL, Rosenblum MG, Zhang HZ, Podoloff DA, Kasi LP, Curley SA, Chan JC, Roh M, Hohn DC, Brewer H.
    Cancer; 1994 Feb 01; 73(3 Suppl):850-7. PubMed ID: 8306270
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.